SCHEMBL6710070

SCHEMBL6710070

O=S(=O)(Nc1cccc(C(F)(F)F)c1)c1ccc(F)c2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 2/20 0.59
CCNB1 P14635 2/20 0.59
CCNA2 P20248 2/20 0.59
CDK2 P24941 2/20 0.59
CDK7 P50613 2/20 0.59
CCNH P51946 2/20 0.59
CCNA1 P78396 2/20 0.59
CCND1 P24385 1/20 0.59
CDK6 Q00534 1/20 0.59
FFAR1 O14842 1/20 0.53
FFAR4 Q5NUL3 1/20 0.53
MAPT P10636 2/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
MAPK1 P28482 1/20 0.52
CYP2C19 P33261 1/20 0.52
THRB P10828 1/20 0.51
IDH1 O75874 7/20 0.51
SLC22A12 Q96S37 2/20 0.50
KMT2A Q03164 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3617602 0.81 TET2 (0.57) FABP4FABP5NPSR1
SCHEMBL3652105 0.81 FABP4 (0.46) SLC22A12FABP4FABP5NPSR1L3MBTL1
SCHEMBL6714314 0.81 SLC22A12 (0.65) SLC22A12FABP4FABP5
SCHEMBL5531152 0.78 FABP4 (0.53) MAPTIDH1KMT2AFABP4FABP5
SCHEMBL6710293 0.78 ACLY (0.57) FFAR1FFAR4IDH1KMT2AFABP4
SCHEMBL3622423 0.77 FABP4 (0.54) SLC22A12FABP4FABP5NPSR1
SCHEMBL1377794 0.77 HTR6 (0.51) CDK1CCNB1CCNA2CDK2CDK7
Hydrochloric Acid SCHEMBL6766422 0.77 FABP4 (0.52) MAPTIDH1KMT2AFABP4FABP5
SCHEMBL120756 0.77 CYP1A2 (0.67) CDK1CCNB1CCNA2CDK2CDK7
SCHEMBL27176707 0.77 CDK1 (0.63) CDK1CCNB1CCNA2CDK2CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1412325-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2004-04-28 EP disclosed
WO-2002100822-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2002-12-19 WO disclosed